A mixed polymeric micelle formulation of paclitaxel (PTX) has been developed with the purpose of improving the solubility and prolonging the time of blood circulation of PTX in comparison to current Taxol injection. The mixed micelles were prepared by thin-ˆlm method using a nonionic surfactant Pluronic P105, L101 and PTX. The mean size of PTX-loaded mixed micelles was 185 nm with narrow size distribution shown by a dynamic light scattering sizer and a transmission electron microscopy. The in vitro release proˆles indicated that PTX release from the mixed micelles exhibited a sustained release behavior. A similar phenomenon was also observed in a pharmacokinetic assessment in rats, in which t 1/2b and AUC of the mixed micelle formulation were 5.5 and 4.9-fold higher than that of Taxol injection. The biodistribution study in mice showed that the PTX-loaded mixed micelles not only decreased drug uptake by liver, but also prolonged drug retention in blood, and increased distribution of the drug in lung, spleen and kidney. These results suggested that the mixed polymeric micelles may e‹ciently load, protect and retain PTX in both in vitro and in vivo environments, and could be a useful drug carrier for intravenous administration of PTX.
INTRODUCTION
Polymeric micelles possess several advantages compared with micelles formed from low molecular weight surfactants, including good structural stability, slow dissociation rate, low critical micelle concentration (CMC), easy control of particle size, good solubilization of hydrophobic drugs, etc. 1,2) They can accumulate anticancer drugs in tumors, release drugs for an extended time, and prevent rapid clearance by the reticular endothelial system (RES) because of their size and surface characteristics. 3) They have been applied in theˆeld of drug targeting because of the unique characteristics in the body. Generally, amphiphilic block or graft copolymers composed of hydrophilic and hydrophobic segments will self-assemble into polymeric micelles when their concentration is above their CMC. So far, many types of block copolymers have been used to deliver anticancer drug into various tumors, including poly(ether)-block-poly(ester), poly(ether)-block-poly(L-amino acid), poly(ether)-block-polycation, poly (ether)-blockpoly (ether), etc. 4, 5) Among these block copolymers, Pluronics, triblock poly (ethylene oxide) (PEO) and poly (propylene oxide) (PPO) based copolymers, have been commonly used as micellar nanocontainers to solubilize hydrophobic drugs. 6) Recently, it was found that Pluronics as a biological response modiˆer could interact with multidrug resistant (MDR) cancer cells resulting in drastic sensitization of these tumors with respect to doxorubicin 7) and other anticancer agents, such as paclitaxel (PTX). 8) Pluronics have been used in pharmaceutics for the controlled release of drugs, which can prolong blood circulation time and change the biodistribution of drugs. Illum et al. demonstrated that it was possible to signiˆcantly alter the in vitro interaction with isolated macrophages and the biodistribution of model polystyrene nanospheres after coating the particle surface with a Pluronic. 9, 10) Additionally, we also reported that PTX-loaded Pluronic P123 micelles could eŠectively prolong blood circulation time and modify the biodistribution of PTX in vivo 11) and exert higher cytotoxicity against resistant human ovarian tumor cell line, SKOV-3/ PTX (unpublished data). Previously, we have reported on micellar PTX formulation employing Pluronic P105, and have demonstrated that the micellar PTX could increase the cytotoxicity against MCF-7/ADR, resistant breast tumor cell line. However, the drug-loading contents and encapsulation ratio of the PTX-loaded Pluronic P105 micelles are relatively low compared with other PTXloaded polymeric micelles reported elsewhere. In order to improve the loading characteristics of Pluronic micellar PTX, a small percentage of hydrophobic, lamella-forming L101 was added into the hydrophilic P105 micellar system to form a mixed micelle. The results has demonstrated that the mixed micellar system (P105/L101＝8/1, w/w) increased the volume of the hydrophobic region of the micelle and particle size, and exhibited a higher solubilization capacity for the hydrophobic PTX, as well as higher cytotoxicity against MCF-7/ADR compared to PTX-loaded P105 micelles. 8) The aim of this study was to evaluate the in‰uence of the mixed block copolymer micelle carrier(P105/ L101)on the pharmacokinetics and biodistribution of anticancer drug, PTX, in rats and mice. These preliminary results will provide the basis for evaluating in vivo antitumor e‹cacy of the new copolymer micelle, PTX-loaded P105/L101 mixed micelle.
MATERIALS AND METHODS

Drugs and Reagents
Pluronic P105 and L101 were kindly supplied by BASF China Ltd. (Shanghai, China) and used without further treatment. PTX was purchased from Xi'an Sanjiang Bio-Engineering Co. Ltd. (Xi'an, China). Taxol injection (Anzatax Injection Concentrate, 30 mg/5 ml) was produced by FH Faulding & Co. Ltd (Melbourne, Australia). Diazepam was obtained from National Institute for the Control of Pharmaceutical and Biological Products (Beijing, China). All reagents for HPLC analysis, including acetonitrile and methanol were of HPLC grade. Other reagents were of analytical grade.
Animals Sprague-Dawley rats (220±30 g) and female Kunming strain mice (20±5 g) were supplied by Laboratory Animal Center of Fudan University, Shanghai, China. The animals were used following the guideline of the Ethical Committee for Animal Experiments of Fudan University. The animals were acclimatized at a temperature of 25±2°C and a relative humidity of 70±5％ under natural light/dark conditions for at least 24 h before dosing.
Preparation of PTX-loaded Mixed Micelles PTX-loaded mixed micelle was prepared by thinˆlm method. 12) Brie‰y, 6 mg PTX, 266 mg P105 and 34 mg L101 samples were dissolved in 10 ml acetonitrile in a round-bottom ‰ask. The solvent was removed by rotary evaporation at 60°C for 1 h to obtain a solid PTX/copolymer matrix, and then the solid PTX/ copolymer matrix was hydrated with 5 ml H 2 O at 70°C to obtain a clear micellar solution. The unincorporated drug aggregates were removed by passing through 0.22 mmˆlters (Millipore), followed by lyophilization.
Characterization of Mixed Micelles Drug-loading coe‹cient (DL％) and encapsulation ratio (ER ％) were calculated as described earlier. 13, 14) Firstly, PTX was extracted from the mixed micelles with acetonitrile, and then the extract solution was properly diluted prior to HPLC analysis. The content of PTX in the mixed micelles was determined by HPLC method described below. Then, DL％ and ER％ were calculated according to Eqs. (1) and (2):
(2) Where W P is the weight of initial feeding polymer, W M is the weight of drug incorporated in the mixed micelles, and W F is the weight of initial feeding drug.
Particle size distribution and mean diameter of the prepared mixed micelles were determined by dynamic light scattering using a NICOMP 380 Submicron Particle Sizer (Santa Barbara, CA, USA) equipped with a 5 mW heliumneon laser at 632.8 nm. Sample solutionsˆltered through a 0.22 mmˆlter membrane were transferred into the light scattering cells. The intensity autocorrelation was measured at a scattering angle of 90°at room temperature.. Data were analyzed in terms of intensity-weighted NICOMP distributions. Each reported experimental result is the average of at least three˜d h values obtained from analysis of the autocorrelation function accumulated for at least 20 min. The morphological examination of the mixed micelles was performed using a transmission electron microscope (Philips CM120, Netherlands). A drop of micellar solution containing 0.1％ (w: v) phosphotungstic acids was placed on a carbonˆlm coated on a copper grid and observed at 80 kV in the electron microscope.
In Vitro Release of PTX from Mixed Micelles The in vitro release properties of PTX from the mixed micelles were investigated in an aqueous medium containing 1 mol/l sodium salicylate by a dialysis method. 15) 1 ml of micellar PTX solution (0.1 mg/ml PTX) was introduced into a dialysis bag (MWCO＝ 14 kDa, Greenbird Inc., Shanghai, China). The end-sealed dialysis bag was immersed into 50 ml 1 mol/l sodium salicylate solution at 37°C. The release medium was stirred at the speed of 75 rpm for 24 h. Samples of 0.5 ml were withdrawn at diŠerent time intervals (0, 10, 20, 30, 45 min, and 1, 2, 4, 6, 9, 12, 24 h) and replaced with an equal volume of fresh release medium. The concentration of PTX in the samples was determined by the HPLC method described below. PTX release from the PTX stock solution and Taxol injection placed in a dialysis bag was conducted under the same conditions as controls. The PTX stock solution was prepared using 0.1％ dimethyl sulfoxide (DMSO) and phosphate buŠered saline (PBS) as a solvent, and the concentration of PTX stock solution used as a control is 0.1 mg/ml PTX.
Pharmacokinetic Studies Twelve SpragueDawley rats were used to investigate the eŠect of formulation on the pharmacokinetics of PTX after intravenous administration. Rats were divided into 2 groups at random, and given a single 6 mg/kg dose of Taxol injection or PTX-loaded mixed micelles by tailvein injection. The concentration of PTX in the mixed micellar solution for the pharmacokinetic study was 1000 mg/ml. As the control, Taxol injection was diluted 6-fold to 1 mg/ml with 5％ glucose solution shortly before administration.
Blood samples (0.5 ml) were collected into heparinized tubes from the femoral artery at 0 (predose), 5, 15, 30 min, 1, 2, 3, 4, 6, 8 and 12 h after intravenous administration. Blood was immediately processed for plasma by centrifugation at 100×g for 10 min. Plasma samples were frozen and maintained at -70°C until analysis.
Biodistribution Studies Seventy-two female Kunming strain mice were used in the experiment to assess the eŠect of formulation on the biodistribution of PTX after intravenous administration. All mice were divided into 2 groups at random and given a single 3 mg/kg dose of either Taxol injection or PTXloaded mixed micelles by tail-vein injection. At 5, 15, 30 min, 1, 2, 3, 4, 6, and 8 h after drug injection, each animal (n＝4 for each time point) was killed and heart, spleen, lung, liver, kidney, uterus/ovaries, brain as well as blood samples were collected. Tissue samples were washed in ice-cold saline, blotted with paper towel to remove excess ‰uid, weighed and stored at -70°C until assessed for drug concentration by HPLC.
HPLC Analysis
The analysis of PTX levels in vitro and in vivo were carried out using a reversedphase HPLC method on a system equipped with an LC-10ATVP pump, a SPD-10AVP UV-Vis detector (Shimadzu, Kyoto, Japan) and a HS2000 interface (Empire Science & Tech, Hangzhou, China) operated at 230 nm. A reversed-phase column (Gemini 5 mm C18, 150×4.6 mm, Phenomenex, California, USA) was used at room temperature. The mobile phase consisted of acetonitrile, and ammonium acetate buŠer solution (10 mmol/l, pH 5.0) (50：45, v/v) was freshly prepared for each run and degassed before use. Samples of 20 ml were injected into the HPLC column for all the analysis. The retention time of PTX was approximately 8.2 min with a ‰ow rate of 1.0 ml/min for the mobile phase. Tissue samples were homogenized in the mixed solution of acetonitrile and water (50：50, v/v). Diazepam (1 mg/ml, 50 ml) as internal standard was added into 200 ml of plasma or tissue samples and vortexed for 1 min. The drug and internal standard were then extracted into 3 ml of diethyl ether by vortex mixing for 2 min. After centrifugation at 6000×g for 10 min, the clear supernatant was removed and evaporated under a gentle stream of nitrogen. The residue was then dissolved by 100 ml acetonitrile and centrifuged at 1500×g for 5 min before HPLC analysis.
Statistical Analysis The compartment of model was simulated by a 3p97 program (Practical Pharmacokinetic Program 1997, China), whereby the parameters of pharmacokinetics were calculated. The calculation of AUC (area under the plasma concentration-time curve) was based on statistical moment theory. The pharmacokinetic parameters were analyzed for statistical signiˆcance by unpaired Student's t-test. For this purpose the level of signiˆcance was set at a＝0.05. In the biodistribution studies, the AUC could not be determined in individual mice because of the destructive study design.
RESULTS
Preparation and Characterization of PTX-loaded Mixed Micelles
The Pluronic block copolymers used in this work and their characteristics are presented in Table 1 . The CMC values of P105 and L101 determined using iodine incorporation UV spectroscopy technique 16) were found to be 0.006％ and 0.0008％, respectively. It was consistent with previous reports that the CMC values of the Pluronic P105 and L101, determined using pyrene solubilization technique, was 0.004％ (6.2×10 -6 M) and 0.0008％ at 37°C. 17) Amphiphilic Pluronic diblock copolymers can form spherical micelles when their concentration is at or above their CMC in an aqueous environment. Hydrophobic drugs can be physically incorporated within the cores of the polymeric micelles by hydrophobic interactions. In this work, the diameter of the PTX-loaded mixed micelles (P105/L101＝8： 1, w/w) was 185 nm, and a narrow size distribution was conˆrmed by dynamic light scattering (DLS) measurement (Fig. 1) . In addition, the mean diameter of PTX-unloaded mixed micelles was 176.8 nm, which was not signiˆcantly diŠerent compared to the PTX-loaded mixed micelles ( p＞0.05). The drug loading coe‹cient (DL％) and the encapsulation ratio (ER％) were 1.7％ and 83.3％, respectively (Table 1). Furthermore, the morphology of PTX-loaded mixed micelle observed with transmission electron microscope (TEM) revealed that the mixed micelles had a spherical shape and no drug crystal was visible (Data not shown).
In Vitro Release of PTX from Mixed Micelles The theoretical maximum concentration of PTX in this aqueous medium is about 2.0 mg/ml assuming complete release of the PTX incorporated in the mixed micelles, while the solubility of PTX in this release medium is about 28.1 mg/ml. 15) Therefore, this system could maintain a good sink condition for the in vitro release studies of PTX by using the aqueous release medium containing 1 mol/l sodium salicylate which solubilized more than 10 times the total amount of PTX incorporated in the mixed micelles.
PTX was continuously released from the mixed micelles in this aqueous release medium for 24 h at 37°C. PTX release from the PTX stock solution and Taxol injection were investigated as controls. The results of the cumulative PTX release proˆle from the mixed micelle are shown in Fig. 2 . During a 6-h period, 100％ PTX was released form the PTX stock solution, and 95.2％ PTX from Taxol injection. There was not signiˆcantly diŠerent in the PTX release from the Taxol injection and the stock solution (p＞0.05). During the same period, only 78.4％ PTX was released from the mixed micelles, which showed signiˆcant diŠerence compared with Taxol injection ( p＜0.05). During a 24-h period, the mixed micelle cumulatively released 90.7％ PTX.
Pharmacokinetics of PTX-loaded Mixed Micelle The HPLC method for analysis has been validated. Linearity in the standard curves was demonstrated over the concentration range studied, and endogenous components had no interference in the chromatograms. The LOD (limit of detection) for PTX deˆned as a minimum signal-to-noise of three was 10 ng/ml. The intra-day accuracy (deviation) was within 5％, and the intra-day precision (R.S.D.) was less than 4％. The inter-day accuracy and precision were within 11％ and 10％, respectively. Figure 3 shows the mean plasma concentration-time proˆles of PTX in blood after intravenous administration of the PTX-loaded mixed micelles and Taxol injection at a single dose of 6 mg/kg, respectively. A two-compartment open model with 1/C weight wasˆtted to the plasma PTX concentration using a computer program 3p97. The related pharmacokinetic parameters are listed in Table 2 , and analyzed for statistical signiˆcance by unpaired Student's t-test. The plasma concentration of PTX delivered by the mixed micelles was higher than Taxol injection during all experimental hours. The former provided signiˆcantly higher (4.9 fold) AUC compared to the latter (p＜0.01). The concentrations showed a rapid decline in distribution phase for theˆrst 0.4 h after dosing with two preparations. The t 1/2a (distribution half-life) showed signiˆcant diŠerence (p＜0.05) between two groups, and the corresponding values were 0.33 h and 0.11 h for the mixed micelles and Taxol injection, respectively. The t 1/2b (elimination half-life). of the mixed micelles and Taxol injection was 6.99 h and 1.27 h, respectively. The statistical analysis of the t 1/2b , Cl (clearance), k 10 (central compartment elimination rate constant) (p＜0.01) and k 21 (elimination rate constant from peripheral to central compartment) (p ＜0.05) showed signiˆcant diŠerences between two groups. These data indicated that the mixed micelles increased the systemic circulation time of PTX, which was in agreement with the in vitro release of PTX from the mixed micelles.
Biodistribution of PTX-loaded Mixed Micelle In vivo behavior of PTX after intravenous administration of the mixed micelles to mice was investigated with Taxol injection as a control (Fig. 4) . The amounts of drug distributed in unit mass of plasma, heart, spleen, lung, liver, kidney, ovary and uterus of mice at various times were then measured, and the total amount of drug accumulated in each organ within 8 h (AUC 0 8 ) was calculated, and the results are shown in Table 3 . The blood PTX concentration-time Vol. 128 (2008) proˆles observed in mice were similar to the pharmacokinetic study in rats. The time of distribution phase was short and the concentration decreased quickly in this phase. The PTX AUC 0 8 of the mixed micelles was lower in liver, and higher in plasma, lung, spleen, and kidney compared to Taxol injec- tion. There were statistically signiˆcant diŠerences in plasma, liver, spleen, kidney and lung between the mixed micelles and Taxol injection (p＜0.05). However, no signiˆcant diŠerence was observed in heart, ovary and uterus. The AUC 0 8h of these tissues for Taxol injection in a descending order was liver＞ lung＞spleen＞kidney＞ovary and uterus＞heart＞ plasma. In contrast, the corresponding order for the mixed micelle was lung＞kidney＞spleen＞liver＞o-vary and uterus＞heart＞plasma.
DISCUSSION
Like the Pluronic P105 micelles, the PTX-loaded mixed micelles (P105/L101＝8：1, w/w) were prepared by a dialysis method, by which PTX was eŠec-tively encapsulated into the mixed P105/L101 micelles. It was earlier reported that the average particle size of the PTX-loaded P105 micelles was 23.9± 3.0 nm with a narrow particle size distribution, and the drug-loading coe‹cient (DL％) and encapsulation ratio (ER％) of PTX in the P105 micelles were 1.0％ and 54.5％, respectively. 8) In comparison with the P105 micelles, an increased particle size of the mixed micelles (185 nm) was observed when a small percentage of hydrophobic L101 was inserted into the P105 micellar system, and at the same time, the drugloading coe‹cient (DL％) and encapsulation ratio (ER％) of PTX in the mixed micelles were increased to 1.7％ and 83.3％, respectively ( Table 1) . Pluronic P105 block copolymer has an intermediate hydrophile-lipophile balance (HLB) value of 15, which can form sphere micelles in aqueous solution with a small particle size. Pluronic L101 is a hydrophobic Pluronic (HLB1) with long poly (propylene oxide) (PPO) chains and short poly (ethylene oxide) (PEO) chains and can usually form lamellar aggregates with larger sizes (1000 nm) in aqueous solution which exhibit a higher solubilization capacity than spherical micelles formed by hydrophilic Pluronic. 18) These results indicate that insertion of a small percentage of hydrophobic L101 into the P105 micellar system can improve the solubilization capacity of Pluronic P105 for hydrophobic PTX, although PTX is a lipophilic drug whose aqueous solubility at diŠerent pH conditions was around 1.0 mg/ml. 19) Inclusion of surfactants in release media is the most popular method for in vitro PTX release, but the addition of surfactants in release media might have a signiˆcant eŠect on the micellar structure and distort the release proˆles. Cho et al. 15) reported that 1.0 mol/l sodium salicylate solution could solubilize PTX and maintain the sink condition for PTX in aqueous release medium, which did not signiˆcantly aŠect the physical stability of polymeric micelles. In the in vitro release experiment, 1 mol/l sodium salicylate solution was used as a release medium. It was shown that almost all PTX was rapidly released from the PTX stock solution over a 6-h period in this release medium, which indicated that the hindrance eŠect of the dialysis bag was minimal. The cumulative release amount of PTX from Taxol injection in 6 h was around 95％, which was similar to the PTX stock solution. However, there was a sustained PTX release observed from the mixed micelles. The percentage of PTX released in 6 h and in 24 h were only 78.4％ PTX and 90.7％ PTX, respectively, which was much slower than Taxol injection. The cumulative release of PTX from the mixed micelles in 6 h was reduced 1.2-fold compared to that of Taxol injection. In contrast, 45.4％ and 87.8％ PTX were cumulatively released from the PTX-loaded P105 micelles in 6 h and 24 h, respectively (unpublished data). The cumulative release of PTX from the P105 micelles in 6 h were reduced 2.1-fold compared to that of Taxol injection. This indicated that, compared to the P105 micelles, the drug release from the mixed micelles showed much faster during a 6-h period, but remained the same level over a 24-h period, which was presumably related to the diŠerent in vitro stability of the polymeric micelles.
The reticuloendothelial system (RES), especially in the liver, spleen and lung, seems to be responsible for the accumulation of stealth nanoparticles in these organs. Some stealth particles whose surface is decorated with PEG are known to be invisible to macrophages and have prolonged half-lives in the blood compartment. This property endows the particles higher probability to extravasate in pathological sites, like tumors or in‰amed regions where a leaky vascular structure is developed. 20 22) The in vivo pharmacokinetics and biodistribution studies of the PTXloaded mixed micelles in rats indicated the hydrophilic shell of Pluronic P105 of the mixed micelles could make the micellar PTX avoid the recognition and uptake by the reticuloendothelial systems (RES) and prolong the time of blood circulation of PTX. This eŠect of the mixed micelles resulted in a slower clearance (0.22-fold), as well as higher t 1/2b (5.50-fold) and AUC (4.92-fold) than Taxol injection (p＜0.01) in the pharmacokinetics study. The higher AUC (1.53-fold) in plasma of the PTX-loaded mixed micelles than Taxol injection in biodistribution study was also a result of this eŠect. In one aspect, although there is a discrepancy of blood concentrations of PTX between rats and mice which is probably due to species diŠerences or administration of diŠerent doses of the PTX mixed micelles, the in vivo prolonged retention of PTX in plasma is consistent with the in vitro sustained release behaviors of this drug from the mixed micelles. In other aspect, this phenomenon is probably related to a signiˆcant decrease of hepatic distribution of PTX. In mouse tissue distribution study, a lower AUC of the mixed micelles was seen in liver. The Kp (tissue to plasma concentration ratio) values of PTX in liver are 9.25 and 37.7 after the mixed micelle and Taxol injection administration, respectively. This 4-fold decrease in the hepatic distribution of the PTX-loaded mixed micelle causes reduction of hepatic clearance of PTX, which has a great impact on its plasma concentration because PTX elimination is primarily by the hepatic metabolism by cytochromes P450 2C8 and 3A4. 23) In tissue distribution studies in mice, compared to Taxol injection, higher AUC was found in other REScontaining organs including spleen and lung following intravenous administration of the mixed micelles. However, the Kp values in spleen are almost same between Taxol injection (11.6-fold) and the mixed micelles (13.1-fold), indicating higher concentration in the spleen after the mixed micelle administration is dependent on its higher plasma concentration, not increasing the uptake into the spleen. But the Kp values in lung are signiˆcantly diŠerent between Taxol injection (13.6-fold) and the mixed micelle (38.3-fold). The mechanism or cause of this 2.8-fold increase in the lung distribution of the PTX-loaded mixed micelle is not clear. On the one hand, this phenomenon is presumably related to the intermediately hydrophilic shell formed by PEO segments of the mixed micelles. On the other hand, it is presumably related to the reduced in vivo stability of the mixed micelles, especially in the presence of endogenous components, such as some lung surfactant components, which probably induces aggregation of the mixed micelles in the lung.
Tissue distribution studies also showed that the higher AUC were found in kidney in mice. Generally, amphiphilic polymeric micelles can reduce PTX uptake by the kidney. However, the AUC of PTX of the mixed micelles in kidney was higher than Taxol injection in our research. This may be explained by the biological property of Pluronic P105. It was earlier reported that Pluronics were excreted primarily through the kidneys. 24) The clearance in rats, dogs, and humans was shown to be almost entirely by renal excretion. Some studies showed that the formation of micelles had no eŠect on the elimination clearance of the block copolymer. 25) The biodistribution study of Pluronic P105 micelles also showed that the concentration of this material accumulated in kidney cells was higher than the other organs in mice after i.p. injections. 26) Therefore, the mixed micelles comprised of P105 and L101(8：1, w：w) leading to an increment in AUC of PTX in kidney could be induced. In addition, there is not signiˆcantly diŠerent in the biodistribution proˆles of the mixed micelles and Taxol injection in mouse brain, which were so low that most of these samples could not be accurately measured because the concentrations were below the quantitation limit. This phenomenon is consistent with the previous literature reported by Rowinsky and Donehower. 27) In contrast with the P105 micelles, the mixed micelles showed the similar pharmacokinetics and biodistribution properties. The t 1/2b and AUC of the P105 micelles in rats in the pharmacokinetics studies were 4.9-fold and 5.3-fold higher compared to Taxol injection, respectively, and its AUC in plasma in mice in the biodistribution studies was 1.6-fold higher than that of Taxol injection. The PTX AUC of the P105 micelles was also lower in liver, and higher in plasma, spleen, lung, and kidney in mice in the biodistribution studies compared to Taxol injection (unpublished data). These data indicate that insertion of a small percentage of hydrophobic L101 (1/9, w/w) into the spherical P105 micelles can signiˆcantly improve the solubilization strength for hydrophobic PTX, but a small percentage of hydrophobic L101 in the P105 micellar system can not signiˆcantly change its in vivo behavior.
On the basis of these preliminary results, a study on evaluating in vivo antitumor e‹cacy of the PTXloaded mixed micelles (P105/L101, 8/1) on BALB/c nude mice bearing s.c. human resistant ovarian SKOV-3/PTX carcinoma is under investigation in our laboratory.
CONCLUSION
In summary, in vitro characteristics of the PTXloaded mixed micelles (P105/L101, 8/1) and in vivo pharmacokinetics and biodistribution of PTX delivered by the mixed micelle carriers were demonstrated. The mixed micelles may e‹ciently load, protect and retain PTX in both in vitro and in vivo environments. In vitro release proˆles indicated that PTX release from the mixed micelles exhibited a sustained release behavior. A similar phenomenon was also observed in plasma in rats. Incorporating PTX in the mixed micelles not only decreased drug uptake by liver, but also prolonged drug retention in the blood, and increased the distribution of drug in spleen, lung, and kidney in mice. These results suggested that the mixed P105/L101 micellar formulation can provide a useful alternative dosage forms for intravenous administration of PTX.
